Skip to main content
Figure 2 | BMC Nephrology

Figure 2

From: Maintaining over time Clinical Performance targets on Anaemia correction in unselected population on chronic dialysis at 20 Italian Centres. Data from a retrospective study for a Clinical Audit

Figure 2

Erythropoietin doses in patients suffering from malignancies or myeloma vs. non-neoplastic patients. Patients who developed malignancies or myeloma during the observation period were excluded. CI: Confidence Interval. Patients with Malignancies/myeloma n. 44: Mean Erythropoietin (IU/Kg/wk): 206.75 (CI 95%, 174.70: 238.79). Patients without Malignancies/myeloma n. 413: Mean Erythropoietin (IU/Kg/Wk): 136.66 (CI 95%, 126.20: 147.12). P < 0.0001. The averages and medians of Erythropoietin doses seem consistently higher in the group of patients with cancer or myeloma but the difference evaluated by the non-parametric method was not statistically significant.

Back to article page